Sanofi gets EU approval for Sarclisa for newly diagnosed patients
Sanofi (NASDAQ:SNY) has received EU regulatory approval for its drug Sarclisa for the treatment of newly diagnosed multiple myeloma patients. The drug was approved for use in combination with a ...
STAT5h
Pharmalittle: We’re reading about a cancer therapy’s gold rush, FDA warning Sanofi, and more news
A Belgian court dismissed a lawsuit against EU chief Ursula von der Leyen centered on text messages she exchanged with Pfizer ...
The Pharma Letter7h
FDA sends Sanofi warning letter over quality violations
The FDA issues a warning letter to Sanofi over manufacturing violations at its Massachusetts site, citing contamination and ...
The Pharma Letter8h
Sarclisa gains European nod for first-line multiple myeloma
Sanofi secures EU approval for Sarclisa with VRd for newly diagnosed multiple myeloma patients ineligible for stem cell ...
clinicaltrialsarena9h
FDA lifts hold on Opella’s trial to support switch of Cialis to OTC drug
The US FDA has removed the clinical hold on a trial of Cialis (tadalafil) by Sanofi's consumer healthcare business, Opella.
Hosted on MSN10h
Global Fund Unveils Pioneering Climate and Health Fund to Accelerate Global Action
The new fund targets the world's most climate-vulnerable nations, delivering urgent support on adaptation and strengthening health systems to safeguard millions from the intensifying impacts of ...
Sanofi Announces Expanded Marketing Authorization For Sarclisa In The EU - Quick Facts
Sanofi (SNYNF, SNY) said the EU has approved Sarclisa in combination with a standard-of-care regimen, bortezomib, lenalidomide, and ...
BioWorld22h
BioWorld Asia, Clinical
China's National Medical Products Administration (NMPA) approved Innovent Biologics Inc.’s NDA for Dovbleron (taletrectinib), a next-generation ROS1 tyrosine kinase inhibitor (TKI), for treating ...